Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246364 | 0.84 | PTK2 (0.49) | MAPTL3MBTL1POLBTDP1TP53 | |
| SCHEMBL11868017 | 0.82 | MAPT (0.64) | MAPTL3MBTL1POLBTDP1TP53 | |
| SCHEMBL21488925 | 0.81 | MAPT (0.43) | MAPTL3MBTL1POLBTP53MEN1 | |
| SCHEMBL25083579 | 0.80 | MEN1 (0.47) | MAPTL3MBTL1MEN1KMT2AANO1 | |
| SCHEMBL11468077 | 0.78 | TP53 (0.62) | MAPTPOLBTDP1TP53MEN1 | |
| SCHEMBL3801340 | 0.78 | MAPT (0.39) | MAPTTDP1MEN1KMT2AANO1 | |
| SCHEMBL23413553 | 0.77 | MEN1 (0.45) | MAPTL3MBTL1POLBTP53MEN1 | |
| SCHEMBL14882354 | 0.77 | MEN1 (0.40) | MAPTMEN1KMT2AANO1MAPK8 | |
| SCHEMBL29515001 | 0.77 | ALDH1A1 (0.55) | MAPTTDP1TP53MEN1KMT2A | |
| SCHEMBL19494292 | 0.76 | MAPT (0.42) | MAPTL3MBTL1POLBTDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118970176-A | Electrolyte and battery | 惠州亿纬锂能股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-3774815-A1 | THIENOPYRIMIDINONE COMPOUNDS | Biotheryx Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10584133-B2 | Thienopyrimidinone compounds | BIOTHERYX, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190322682-A1 | THIENOPYRIMIDINONE COMPOUNDS | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| WO-2019191451-A1 | THIENOPYRIMIDINONE COMPOUNDS | BIOTHERYX, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-4658040-A | Process for manufacturing heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-14 | — | — | US | disclosed |
| US-4211696-A | Disperse monoazo dyestuffs derived from 3,5-dinitro-2-amino thiophene as disazo component and an arylamine coupling component | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322682-A1 | THIENOPYRIMIDINONE COMPOUNDS | MAVS, BRCA1, HSPE1 | MAPT 1007/4885L3MBTL1 641/4885POLB 1737/4885 |
| US-10584133-B2 | Thienopyrimidinone compounds | MAVS, BRCA1, HSPE1 | MAPT 1007/4885L3MBTL1 641/4885POLB 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.